🇪🇺 Hexaxim® in European Union

EMA authorised Hexaxim® on 17 April 2013

Marketing authorisations

EMA — authorised 17 April 2013

  • Application: EMEA/H/C/002702
  • Marketing authorisation holder: Sanofi Winthrop Industrie
  • Local brand name: Hexacima
  • Indication: Hexacima (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The use of this vaccine should be in accordance with official recommendations.
  • Status: approved

Read official source →

EMA — authorised 17 April 2013

  • Application: EMEA/H/C/002796
  • Marketing authorisation holder: Sanofi Winthrop Industrie
  • Local brand name: Hexyon
  • Indication: Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The use of this vaccine should be in accordance with official recommendations.
  • Status: approved

Read official source →

Other Immunology approved in European Union

Frequently asked questions

Is Hexaxim® approved in European Union?

Yes. EMA authorised it on 17 April 2013; EMA authorised it on 17 April 2013.

Who is the marketing authorisation holder for Hexaxim® in European Union?

Sanofi Winthrop Industrie holds the EU marketing authorisation.